NCT01812148

Survival of Peritoneal Mesothelioma After Cytoreductive Surgery and Hyperthermic Intra-peritoneal Chemotherapy (HIPEC)

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 19 (actual)
• Sponsor: Maisonneuve-Rosemont Hospital · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

Review of the investigators hospital experience in cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy (HIPEC) for peritoneal mesotheliomas, using Oxaliplatin as intraperitoneal chemotherapeutic agent.

Detailed description

Observation of primary outcome: * Overall Survival * Disease-free survival Influencing factors that will be observe: * Sex * Blood loss * Time of surgery * Number of resection and anastomosis * Peritoneal Index (PI score) * Cytoreductibility (CCR score)

Conditions

• Peritoneal Mesotheliomas

Interventions

Type	Name	Description
PROCEDURE	Cytoreductive surgery and HIPEC	Cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy (HIPEC) with Oxaliplatin as chemotherapeutic agent

Timeline

• Start date: 2012-01-01
• Primary completion: 2013-03-01
• Completion: 2013-03-01
• First posted: 2013-03-18
• Last updated: 2013-03-18

Locations

1 site across 1 country: Canada